<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03816189</url>
  </required_header>
  <id_info>
    <org_study_id>2017_10</org_study_id>
    <secondary_id>2017-A02587-46</secondary_id>
    <nct_id>NCT03816189</nct_id>
  </id_info>
  <brief_title>Role of Eosinophil in Fibrogenesis of Systemic Sclerosis</brief_title>
  <acronym>EOFIB-SSC</acronym>
  <official_title>Role of Blood and Tissue Eosinophils in the Fibrogenesis of Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophils are involved in tissue remodeling and fibrosis in many inflammatory diseases.
      Systemic sclerosis (SSc) is an autoimmune disease with fibrotic skin and lung complications.
      The profibrosing properties and data from the SSc literature suggest a possible role of the
      eosinophils in the process of fibrogenesis of SSc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      it will assess the activation state of blood eosinophils in SSc patients compared to healthy
      controls (ECP production in vitro, surface activation markers, whole transcriptome array,
      ..).

      it will also study skin eosinophils and their recruitment (extracellular eosinophil granules,
      eotaxins production in skin, ..)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of ECP concentrations in supernatants of eosinophils culture</measure>
    <time_frame>Baseline: one session</time_frame>
    <description>Eosinophils will be sorted, stimulated in vitro for 2 hours and ECP concentration will be assessed in supernatants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of median fluorescence intensities of several surface markers on blood eosinophils, or comparison of percentages of positive cells among all eosinophils for a given marker (flow cytometry)</measure>
    <time_frame>Baseline: one session</time_frame>
    <description>MFI/% of CD69, HLA class II, CD9, CD11c, CD44, CCR3, CRTH2, IL-5R on blood eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiles will be compared between SSc patients and healthy controls (whole transcriptome assay)</measure>
    <time_frame>Baseline: one session</time_frame>
    <description>Whole genome, transcriptomic approach (differentially expressed genes will be identified using a fold change cutoff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In skin biopsies: density of eosinophils, extracellular ECP and MBP deposits (absent in healthy skin), and density of eotaxin-1-producing cells will be assessed in damaged skin and apparently healthy skin of SSc patients</measure>
    <time_frame>Baseline: one session</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>Diffuse SSc</arm_group_label>
    <description>Recruitment of 20 patients with diffuse SSc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Limited SSc</arm_group_label>
    <description>Recruitment of 20 patients with limited SSc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Recruitment of 20 healthy subjects (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing</description>
    <arm_group_label>Diffuse SSc</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Limited SSc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin biopsies</intervention_name>
    <description>In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)</description>
    <arm_group_label>Diffuse SSc</arm_group_label>
    <arm_group_label>Limited SSc</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Eosinophils, tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The active line of the Internal Medicine department (&gt; 400 sclerodermic patients)
        guarantees the recruitment of 20 diffuse forms and 20 limited forms
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For SSc patients:

          -  Meeting the 2013 ACR-EULAR criteria for diffuse SSc (n = 20) and limited SSc (n = 20)

          -  Having signed the informed consent

          -  Eosinophils ≥ 0.1 G / L on the last blood test (&lt;3 months)

        For healthy subjects:

          -  Without chronic pathology requiring long-term treatment

          -  Eosinophils between 0.1 and 0.4 G / L on recent blood test (&lt;3 months)

        Exclusion Criteria for patients and controls:

          -  Patient with an infection, state of emergency or progressive neoplastic pathology

          -  Pregnant or lactating women

          -  History of atopy (allergic asthma, atopic eczema, allergic rhinitis, allergic
             conjunctivitis)

          -  Allergy to local anesthetics (for scleroderma patients only)

          -  Taking into account a minimum weight of 50 kg and in the absence of cardiorespiratory
             effects of scleroderma, only patients with at least 10 g of hemoglobin will be
             included
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Lefevre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Lefevre, MD, PhD</last_name>
    <phone>320446662</phone>
    <phone_ext>+33</phone_ext>
    <email>guillaume.lefevre@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillaume Lefevre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophil</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Systemic Scleroderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

